Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $290

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $395 to $290.
byBenzinga Newsdesk
October 8, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Carter Gould maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $395 to $290.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0